211 related articles for article (PubMed ID: 36157769)
1. Pharmacophore-Based Virtual Screening and Experimental Validation of Pyrazolone-Derived Inhibitors toward Janus Kinases.
Sanachai K; Mahalapbutr P; Hengphasatporn K; Shigeta Y; Seetaha S; Tabtimmai L; Langer T; Wolschann P; Kittikool T; Yotphan S; Choowongkomon K; Rungrotmongkol T
ACS Omega; 2022 Sep; 7(37):33548-33559. PubMed ID: 36157769
[TBL] [Abstract][Full Text] [Related]
2. Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases.
Sanachai K; Mahalapbutr P; Choowongkomon K; Poo-Arporn RP; Wolschann P; Rungrotmongkol T
ACS Omega; 2020 Jan; 5(1):369-377. PubMed ID: 31956784
[TBL] [Abstract][Full Text] [Related]
3. Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds.
Sanachai K; Mahalapbutr P; Tabtimmai L; Seetaha S; Kittikool T; Yotphan S; Choowongkomon K; Rungrotmongkol T
ACS Omega; 2022 Sep; 7(37):33587-33598. PubMed ID: 36157733
[TBL] [Abstract][Full Text] [Related]
4. In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones.
Sanachai K; Mahalapbutr P; Tabtimmai L; Seetaha S; Kaekratoke N; Chamni S; Azam SS; Choowongkomon K; Rungrotmongkol T
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677654
[TBL] [Abstract][Full Text] [Related]
5. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach.
Jasuja H; Chadha N; Kaur M; Silakari O
Mol Divers; 2014 May; 18(2):253-67. PubMed ID: 24415188
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore and Virtual Screening of JAK3 inhibitors.
Rajeswari M; Santhi N; Bhuvaneswari V
Bioinformation; 2014; 10(3):157-63. PubMed ID: 24748756
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
Liang X; Huang Y; Zang J; Gao Q; Wang B; Xu W; Zhang Y
Bioorg Med Chem; 2016 Jun; 24(12):2660-72. PubMed ID: 27137359
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
11. Putative dual inhibitors of Janus kinase 1 and 3 (JAK1/3): Pharmacophore based hierarchical virtual screening.
Jasuja H; Chadha N; Singh PK; Kaur M; Bahia MS; Silakari O
Comput Biol Chem; 2018 Oct; 76():109-117. PubMed ID: 29990790
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.
Ma X; Diao Y; Ge H; Xu F; Zhu L; Zhao Z; Li H
Bioorg Med Chem Lett; 2020 Apr; 30(8):127048. PubMed ID: 32122740
[TBL] [Abstract][Full Text] [Related]
13. Searching for Novel Janus Kinase-2 Inhibitors Using a Combination of Pharmacophore Modeling, 3D-QSAR Studies and Virtual Screening.
Vrontaki E; Melagraki G; Afantitis A; Mavromoustakos T; Kollias G
Mini Rev Med Chem; 2017; 17(3):268-294. PubMed ID: 27659251
[TBL] [Abstract][Full Text] [Related]
14. CXCL12 signaling is independent of Jak2 and Jak3.
Moriguchi M; Hissong BD; Gadina M; Yamaoka K; Tiffany HL; Murphy PM; Candotti F; O'Shea JJ
J Biol Chem; 2005 Apr; 280(17):17408-14. PubMed ID: 15611059
[TBL] [Abstract][Full Text] [Related]
15. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
17. JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.
Nishiya N; Sakamoto Y; Oku Y; Nonaka T; Uehara Y
World J Biol Chem; 2015 Nov; 6(4):409-18. PubMed ID: 26629323
[TBL] [Abstract][Full Text] [Related]
18. Computer-aided discovery of aminopyridines as novel JAK2 inhibitors.
Zhao C; Yang SH; Khadka DB; Jin Y; Lee KT; Cho WJ
Bioorg Med Chem; 2015 Mar; 23(5):985-95. PubMed ID: 25650310
[TBL] [Abstract][Full Text] [Related]
19. Identification of Chinese Herbal Compounds with Potential as JAK3 Inhibitors.
Su D; Gao YQ; Deng YJ; Zhang HH; Wu YR; Hu Y; Mei QX
Evid Based Complement Alternat Med; 2019; 2019():4982062. PubMed ID: 31093295
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.
Kaur M; Singh PK; Singh M; Bahadur R; Silakari O
Mol Divers; 2018 Feb; 22(1):95-112. PubMed ID: 29138965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
